Theratechnologies Inc. re-affirmed revenue guidance for the fiscal year of 2022. For the year, the company is on track to be in the range of $79 million - $82 million, or growth of the commercial portfolio to be in the range of 13% and 17%, as compared to the 2021 fiscal year.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.81 CAD | +1.69% | +9.04% | -15.42% |
May. 09 | Theratechnologies Inc. Announces Frank Holler as Chair of the Board of Directors | CI |
May. 09 | Transcript : Theratechnologies Inc. - Shareholder/Analyst Call |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.42% | 59.96M | |
-1.26% | 89.46B | |
+2.76% | 40.74B | |
-8.58% | 33.03B | |
+55.32% | 24.68B | |
-16.42% | 15.12B | |
-8.90% | 12.81B | |
-12.11% | 11.79B | |
-43.61% | 11.64B | |
+7.79% | 8.9B |
- Stock Market
- Equities
- TH Stock
- News Theratechnologies Inc.
- Theratechnologies Inc. Re-Affirms Revenue Guidance for the Fiscal Year of 2022